Robert Ronn - Orexo AB Vice President and Head of Research & Development

ORXOY Stock  USD 1.00  0.02  2.04%   

President

Mr. Robert Ronn was Vice President and Head of Research Development at Orexo AB since January 2019. He was employed since 2007. He holds MSc in Chemical Engineering and PhD in Medicinal Chemistry, Uppsala University, Sweden. He has previously been Head of Pharmaceutical Development IP at Orexo AB since 2016 and prior to that experience of drug discovery and development, as well as patent prosecution and litigation, from various key positions at Biolipox AB and Orexo AB. since 2019.
Age 47
Tenure 5 years
Phone46 1 87 80 88 00
Webhttps://www.orexo.com

Orexo AB Management Efficiency

The company has return on total asset (ROA) of (0.0965) % which means that it has lost $0.0965 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.6535) %, meaning that it generated substantial loss on money invested by shareholders. Orexo AB's management efficiency ratios could be used to measure how well Orexo AB manages its routine affairs as well as how well it operates its assets and liabilities.
Orexo AB ADR has accumulated 492.3 M in total debt with debt to equity ratio (D/E) of 1.76, which is about average as compared to similar companies. Orexo AB ADR has a current ratio of 2.01, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Orexo AB until it has trouble settling it off, either with new capital or with free cash flow. So, Orexo AB's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Orexo AB ADR sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Orexo to invest in growth at high rates of return. When we think about Orexo AB's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

PRESIDENT Age

Diane BristolVista Outdoor
N/A
Tarrant SibleyHasbro Inc
55
Tracy DawFunko Inc
58
Derek TarleckiVista Outdoor
N/A
Kelly ReisdorfVista Outdoor
44
Masaru KawaguchiBANDAI NAMCO Holdings
63
Jeff SpositoVista Outdoor
N/A
Geoffrey WalkerMattel Inc
58
Debbie HancockHasbro Inc
N/A
Sudhanshu PriyadarshiVista Outdoor
45
Thomas SumnerYamaha Corp DRC
N/A
Tara HefterJAKKS Pacific
N/A
Steve TotzkeMattel Inc
54
Scott WerbelowVista Outdoor
N/A
Greg WilliamsonVista Outdoor
55
Jason VanderbrinkVista Outdoor
46
Ric KernVista Outdoor
N/A
Andrew PerlmutterFunko Inc
47
Robbie BrennerMattel Inc
N/A
Jeffrey McGuaneVista Outdoor
N/A
Vishak SankaranVista Outdoor
N/A
Orexo AB , a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, Europe, and the United Kingdom. Orexo AB was incorporated in 1994 and is headquartered in Uppsala, Sweden. OREXO AB is traded on OTC Exchange in the United States. Orexo AB ADR [ORXOY] is traded as part of a regulated electronic over-the-counter service offered by the NASD.

Management Performance

Orexo AB ADR Leadership Team

Elected by the shareholders, the Orexo AB's board of directors comprises two types of representatives: Orexo AB inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Orexo. The board's role is to monitor Orexo AB's management team and ensure that shareholders' interests are well served. Orexo AB's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Orexo AB's outside directors are responsible for providing unbiased perspectives on the board's policies.
Fredrik Jarrsten, Ex CFO
MD MBA, Chief Officer
Cecilia Coupland, Vice President and Head of Operations
Nikolaj Sorensen, Pres CEO
Lena Wange, Investor Relations & Communications Manager
Jesper Lind, Advisor
Dennis Urbaniak, Ex Therapeutics
Robert DeLuca, President of Orexo US Inc.
Robert Ronn, Vice President and Head of Research & Development

Orexo Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Orexo AB a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Orexo OTC Stock Analysis

When running Orexo AB's price analysis, check to measure Orexo AB's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Orexo AB is operating at the current time. Most of Orexo AB's value examination focuses on studying past and present price action to predict the probability of Orexo AB's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Orexo AB's price. Additionally, you may evaluate how the addition of Orexo AB to your portfolios can decrease your overall portfolio volatility.